Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer
Status:
Recruiting
Trial end date:
2022-11-01
Target enrollment:
Participant gender:
Summary
High risk prostate cancer (PCa) had worse outcomes on radical treatment results, short-time
oncological results, even cancer-specific survival, than those low or mediate risk PCa.
Neoadjuvant treatment before radical prostatectomy had been proven to get some benefits on
peri-operation results, especially on reduction of tumor volume and minimization of
biochemical recurrence. This study will evaluate the efficacy and safety of androgen
deprivation therapy (ADT) with abiraterone in neoadjuvant therapy for surgically resectable
high-risk or very high-risk PCa.
Phase:
Phase 2
Details
Lead Sponsor:
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School